nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP1A2—Anagrelide—hematologic cancer	0.0572	0.0847	CbGbCtD
Palonosetron—CYP2D6—Lomustine—hematologic cancer	0.0304	0.045	CbGbCtD
Palonosetron—CYP1A2—Carmustine—hematologic cancer	0.0301	0.0445	CbGbCtD
Palonosetron—CYP2D6—Idarubicin—hematologic cancer	0.0271	0.0401	CbGbCtD
Palonosetron—CYP1A2—Methoxsalen—hematologic cancer	0.0256	0.0378	CbGbCtD
Palonosetron—CYP1A2—Bortezomib—hematologic cancer	0.0243	0.036	CbGbCtD
Palonosetron—CYP1A2—Daunorubicin—hematologic cancer	0.0233	0.0344	CbGbCtD
Palonosetron—CYP2D6—Hydroxyurea—hematologic cancer	0.023	0.0341	CbGbCtD
Palonosetron—CYP1A2—Alitretinoin—hematologic cancer	0.0228	0.0337	CbGbCtD
Palonosetron—CYP1A2—Thalidomide—hematologic cancer	0.0212	0.0314	CbGbCtD
Palonosetron—CYP3A4—Bexarotene—hematologic cancer	0.0208	0.0308	CbGbCtD
Palonosetron—CYP2D6—Bortezomib—hematologic cancer	0.02	0.0297	CbGbCtD
Palonosetron—CYP3A4—Lomustine—hematologic cancer	0.0193	0.0286	CbGbCtD
Palonosetron—CYP3A4—Busulfan—hematologic cancer	0.0193	0.0286	CbGbCtD
Palonosetron—CYP1A2—Dacarbazine—hematologic cancer	0.0182	0.027	CbGbCtD
Palonosetron—CYP1A2—Imatinib—hematologic cancer	0.0178	0.0264	CbGbCtD
Palonosetron—CYP3A4—Thiotepa—hematologic cancer	0.0172	0.0255	CbGbCtD
Palonosetron—CYP2D6—Imatinib—hematologic cancer	0.0147	0.0217	CbGbCtD
Palonosetron—CYP1A2—Dasatinib—hematologic cancer	0.0143	0.0212	CbGbCtD
Palonosetron—CYP3A4—Methoxsalen—hematologic cancer	0.0134	0.0198	CbGbCtD
Palonosetron—CYP2D6—Nilotinib—hematologic cancer	0.0133	0.0197	CbGbCtD
Palonosetron—CYP2D6—Vinorelbine—hematologic cancer	0.0132	0.0196	CbGbCtD
Palonosetron—CYP3A4—Bortezomib—hematologic cancer	0.0127	0.0189	CbGbCtD
Palonosetron—CYP3A4—Daunorubicin—hematologic cancer	0.0122	0.018	CbGbCtD
Palonosetron—CYP3A4—Cytarabine—hematologic cancer	0.0107	0.0159	CbGbCtD
Palonosetron—CYP3A4—Teniposide—hematologic cancer	0.0106	0.0157	CbGbCtD
Palonosetron—CYP3A4—Ifosfamide—hematologic cancer	0.00977	0.0145	CbGbCtD
Palonosetron—CYP3A4—Imatinib—hematologic cancer	0.00933	0.0138	CbGbCtD
Palonosetron—CYP1A2—Etoposide—hematologic cancer	0.00891	0.0132	CbGbCtD
Palonosetron—CYP3A4—Ruxolitinib—hematologic cancer	0.00879	0.013	CbGbCtD
Palonosetron—CYP3A4—Nilotinib—hematologic cancer	0.00848	0.0126	CbGbCtD
Palonosetron—CYP3A4—Vinorelbine—hematologic cancer	0.00841	0.0125	CbGbCtD
Palonosetron—CYP2D6—Vinblastine—hematologic cancer	0.00815	0.0121	CbGbCtD
Palonosetron—CYP3A4—Triamcinolone—hematologic cancer	0.00769	0.0114	CbGbCtD
Palonosetron—CYP3A4—Dasatinib—hematologic cancer	0.0075	0.0111	CbGbCtD
Palonosetron—CYP3A4—Mitoxantrone—hematologic cancer	0.0074	0.011	CbGbCtD
Palonosetron—CYP3A4—Betamethasone—hematologic cancer	0.0066	0.00977	CbGbCtD
Palonosetron—CYP3A4—Prednisolone—hematologic cancer	0.00651	0.00964	CbGbCtD
Palonosetron—CYP3A4—Prednisone—hematologic cancer	0.00615	0.0091	CbGbCtD
Palonosetron—CYP2D6—Dexamethasone—hematologic cancer	0.00604	0.00894	CbGbCtD
Palonosetron—CYP3A4—Irinotecan—hematologic cancer	0.00583	0.00863	CbGbCtD
Palonosetron—CYP3A4—Vinblastine—hematologic cancer	0.00518	0.00767	CbGbCtD
Palonosetron—CYP3A4—Vincristine—hematologic cancer	0.0051	0.00754	CbGbCtD
Palonosetron—CYP2D6—Doxorubicin—hematologic cancer	0.00501	0.00742	CbGbCtD
Palonosetron—CYP3A4—Etoposide—hematologic cancer	0.00467	0.00691	CbGbCtD
Palonosetron—CYP3A4—Dexamethasone—hematologic cancer	0.00384	0.00568	CbGbCtD
Palonosetron—CYP3A4—Doxorubicin—hematologic cancer	0.00318	0.00472	CbGbCtD
Palonosetron—Mental disorder—Methotrexate—hematologic cancer	4.4e-05	0.000147	CcSEcCtD
Palonosetron—Rash—Gemcitabine—hematologic cancer	4.4e-05	0.000147	CcSEcCtD
Palonosetron—Dermatitis—Gemcitabine—hematologic cancer	4.4e-05	0.000147	CcSEcCtD
Palonosetron—Eye disorder—Epirubicin—hematologic cancer	4.4e-05	0.000147	CcSEcCtD
Palonosetron—Hypersensitivity—Etoposide—hematologic cancer	4.39e-05	0.000147	CcSEcCtD
Palonosetron—Tinnitus—Epirubicin—hematologic cancer	4.39e-05	0.000147	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—hematologic cancer	4.38e-05	0.000146	CcSEcCtD
Palonosetron—Erythema—Methotrexate—hematologic cancer	4.38e-05	0.000146	CcSEcCtD
Palonosetron—Headache—Gemcitabine—hematologic cancer	4.37e-05	0.000146	CcSEcCtD
Palonosetron—Nausea—Vincristine—hematologic cancer	4.37e-05	0.000146	CcSEcCtD
Palonosetron—Cardiac disorder—Epirubicin—hematologic cancer	4.37e-05	0.000146	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisolone—hematologic cancer	4.33e-05	0.000145	CcSEcCtD
Palonosetron—Dyspepsia—Betamethasone—hematologic cancer	4.32e-05	0.000145	CcSEcCtD
Palonosetron—Dyspepsia—Dexamethasone—hematologic cancer	4.32e-05	0.000145	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—hematologic cancer	4.3e-05	0.000144	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—hematologic cancer	4.29e-05	0.000143	CcSEcCtD
Palonosetron—Asthenia—Etoposide—hematologic cancer	4.28e-05	0.000143	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—hematologic cancer	4.28e-05	0.000143	CcSEcCtD
Palonosetron—Body temperature increased—Triamcinolone—hematologic cancer	4.28e-05	0.000143	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisone—hematologic cancer	4.27e-05	0.000143	CcSEcCtD
Palonosetron—Angiopathy—Epirubicin—hematologic cancer	4.27e-05	0.000143	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—hematologic cancer	4.27e-05	0.000143	CcSEcCtD
Palonosetron—Decreased appetite—Dexamethasone—hematologic cancer	4.27e-05	0.000143	CcSEcCtD
Palonosetron—Decreased appetite—Betamethasone—hematologic cancer	4.27e-05	0.000143	CcSEcCtD
Palonosetron—Nausea—Irinotecan—hematologic cancer	4.26e-05	0.000142	CcSEcCtD
Palonosetron—Nausea—Mitoxantrone—hematologic cancer	4.26e-05	0.000142	CcSEcCtD
Palonosetron—Immune system disorder—Epirubicin—hematologic cancer	4.25e-05	0.000142	CcSEcCtD
Palonosetron—Infection—Prednisone—hematologic cancer	4.25e-05	0.000142	CcSEcCtD
Palonosetron—Mediastinal disorder—Epirubicin—hematologic cancer	4.24e-05	0.000142	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.24e-05	0.000142	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.24e-05	0.000142	CcSEcCtD
Palonosetron—Fatigue—Betamethasone—hematologic cancer	4.23e-05	0.000142	CcSEcCtD
Palonosetron—Fatigue—Dexamethasone—hematologic cancer	4.23e-05	0.000142	CcSEcCtD
Palonosetron—Chills—Epirubicin—hematologic cancer	4.22e-05	0.000141	CcSEcCtD
Palonosetron—Pruritus—Etoposide—hematologic cancer	4.22e-05	0.000141	CcSEcCtD
Palonosetron—Shock—Prednisone—hematologic cancer	4.2e-05	0.000141	CcSEcCtD
Palonosetron—Arrhythmia—Epirubicin—hematologic cancer	4.2e-05	0.000141	CcSEcCtD
Palonosetron—Pain—Betamethasone—hematologic cancer	4.2e-05	0.00014	CcSEcCtD
Palonosetron—Pain—Dexamethasone—hematologic cancer	4.2e-05	0.00014	CcSEcCtD
Palonosetron—Nervous system disorder—Prednisone—hematologic cancer	4.19e-05	0.00014	CcSEcCtD
Palonosetron—Tachycardia—Prednisone—hematologic cancer	4.17e-05	0.00014	CcSEcCtD
Palonosetron—Alopecia—Epirubicin—hematologic cancer	4.16e-05	0.000139	CcSEcCtD
Palonosetron—Skin disorder—Prednisone—hematologic cancer	4.15e-05	0.000139	CcSEcCtD
Palonosetron—Nausea—Gemcitabine—hematologic cancer	4.15e-05	0.000139	CcSEcCtD
Palonosetron—Vomiting—Cisplatin—hematologic cancer	4.14e-05	0.000138	CcSEcCtD
Palonosetron—Mental disorder—Epirubicin—hematologic cancer	4.12e-05	0.000138	CcSEcCtD
Palonosetron—Rash—Cisplatin—hematologic cancer	4.1e-05	0.000137	CcSEcCtD
Palonosetron—Dermatitis—Cisplatin—hematologic cancer	4.1e-05	0.000137	CcSEcCtD
Palonosetron—Malnutrition—Epirubicin—hematologic cancer	4.1e-05	0.000137	CcSEcCtD
Palonosetron—Erythema—Epirubicin—hematologic cancer	4.1e-05	0.000137	CcSEcCtD
Palonosetron—Diarrhoea—Etoposide—hematologic cancer	4.08e-05	0.000137	CcSEcCtD
Palonosetron—Anorexia—Prednisone—hematologic cancer	4.07e-05	0.000136	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—hematologic cancer	4.07e-05	0.000136	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—hematologic cancer	4.06e-05	0.000136	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—hematologic cancer	4.05e-05	0.000135	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—hematologic cancer	4.04e-05	0.000135	CcSEcCtD
Palonosetron—Flatulence—Epirubicin—hematologic cancer	4.04e-05	0.000135	CcSEcCtD
Palonosetron—Gastrointestinal pain—Betamethasone—hematologic cancer	4.01e-05	0.000134	CcSEcCtD
Palonosetron—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.01e-05	0.000134	CcSEcCtD
Palonosetron—Dysgeusia—Epirubicin—hematologic cancer	4.01e-05	0.000134	CcSEcCtD
Palonosetron—Hypersensitivity—Triamcinolone—hematologic cancer	3.98e-05	0.000133	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—hematologic cancer	3.95e-05	0.000132	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.95e-05	0.00153	CbGpPWpGaD
Palonosetron—Dizziness—Etoposide—hematologic cancer	3.94e-05	0.000132	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—hematologic cancer	3.93e-05	0.000132	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—hematologic cancer	3.92e-05	0.000131	CcSEcCtD
Palonosetron—Chills—Doxorubicin—hematologic cancer	3.91e-05	0.000131	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—RB1—hematologic cancer	3.9e-05	0.00152	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.89e-05	0.00013	CcSEcCtD
Palonosetron—Dizziness—Prednisolone—hematologic cancer	3.89e-05	0.00013	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—hematologic cancer	3.89e-05	0.00013	CcSEcCtD
Palonosetron—Asthenia—Triamcinolone—hematologic cancer	3.88e-05	0.00013	CcSEcCtD
Palonosetron—Abdominal pain—Betamethasone—hematologic cancer	3.88e-05	0.00013	CcSEcCtD
Palonosetron—Abdominal pain—Dexamethasone—hematologic cancer	3.88e-05	0.00013	CcSEcCtD
Palonosetron—Body temperature increased—Betamethasone—hematologic cancer	3.88e-05	0.00013	CcSEcCtD
Palonosetron—Body temperature increased—Dexamethasone—hematologic cancer	3.88e-05	0.00013	CcSEcCtD
Palonosetron—Nausea—Cisplatin—hematologic cancer	3.87e-05	0.000129	CcSEcCtD
Palonosetron—Insomnia—Prednisone—hematologic cancer	3.87e-05	0.000129	CcSEcCtD
Palonosetron—CYP2D6—Biological oxidations—MTR—hematologic cancer	3.86e-05	0.0015	CbGpPWpGaD
Palonosetron—Alopecia—Doxorubicin—hematologic cancer	3.85e-05	0.000129	CcSEcCtD
Palonosetron—Paraesthesia—Prednisone—hematologic cancer	3.84e-05	0.000128	CcSEcCtD
Palonosetron—Pruritus—Triamcinolone—hematologic cancer	3.83e-05	0.000128	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—hematologic cancer	3.81e-05	0.000128	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—hematologic cancer	3.79e-05	0.000127	CcSEcCtD
Palonosetron—Vomiting—Etoposide—hematologic cancer	3.79e-05	0.000127	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—hematologic cancer	3.79e-05	0.000127	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—hematologic cancer	3.79e-05	0.000127	CcSEcCtD
Palonosetron—Anaemia—Epirubicin—hematologic cancer	3.79e-05	0.000127	CcSEcCtD
Palonosetron—CYP1A2—Biological oxidations—UGT1A1—hematologic cancer	3.77e-05	0.00146	CbGpPWpGaD
Palonosetron—Dyspepsia—Prednisone—hematologic cancer	3.76e-05	0.000126	CcSEcCtD
Palonosetron—Rash—Etoposide—hematologic cancer	3.76e-05	0.000126	CcSEcCtD
Palonosetron—Dermatitis—Etoposide—hematologic cancer	3.76e-05	0.000126	CcSEcCtD
Palonosetron—Headache—Etoposide—hematologic cancer	3.74e-05	0.000125	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—hematologic cancer	3.73e-05	0.00145	CbGpPWpGaD
Palonosetron—Flatulence—Doxorubicin—hematologic cancer	3.73e-05	0.000125	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—hematologic cancer	3.73e-05	0.000125	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—hematologic cancer	3.73e-05	0.000125	CcSEcCtD
Palonosetron—CYP1A2—Metapathway biotransformation—UGT1A1—hematologic cancer	3.72e-05	0.00144	CbGpPWpGaD
Palonosetron—Decreased appetite—Prednisone—hematologic cancer	3.72e-05	0.000124	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—hematologic cancer	3.71e-05	0.000124	CcSEcCtD
Palonosetron—Rash—Prednisolone—hematologic cancer	3.71e-05	0.000124	CcSEcCtD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	3.71e-05	0.00144	CbGpPWpGaD
Palonosetron—Dermatitis—Prednisolone—hematologic cancer	3.7e-05	0.000124	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.7e-05	0.000124	CcSEcCtD
Palonosetron—Fatigue—Prednisone—hematologic cancer	3.68e-05	0.000123	CcSEcCtD
Palonosetron—Headache—Prednisolone—hematologic cancer	3.68e-05	0.000123	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—hematologic cancer	3.68e-05	0.000123	CcSEcCtD
Palonosetron—CYP1A2—Phase II conjugation—GSTP1—hematologic cancer	3.68e-05	0.00143	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTT1—hematologic cancer	3.67e-05	0.00143	CbGpPWpGaD
Palonosetron—Constipation—Prednisone—hematologic cancer	3.65e-05	0.000122	CcSEcCtD
Palonosetron—Dizziness—Triamcinolone—hematologic cancer	3.58e-05	0.00012	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—hematologic cancer	3.57e-05	0.00012	CcSEcCtD
Palonosetron—Convulsion—Epirubicin—hematologic cancer	3.55e-05	0.000119	CcSEcCtD
Palonosetron—Infection—Methotrexate—hematologic cancer	3.55e-05	0.000119	CcSEcCtD
Palonosetron—Nausea—Etoposide—hematologic cancer	3.54e-05	0.000119	CcSEcCtD
Palonosetron—Hypertension—Epirubicin—hematologic cancer	3.54e-05	0.000118	CcSEcCtD
Palonosetron—Asthenia—Dexamethasone—hematologic cancer	3.52e-05	0.000118	CcSEcCtD
Palonosetron—Asthenia—Betamethasone—hematologic cancer	3.52e-05	0.000118	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—hematologic cancer	3.5e-05	0.000117	CcSEcCtD
Palonosetron—Anaemia—Doxorubicin—hematologic cancer	3.5e-05	0.000117	CcSEcCtD
Palonosetron—Gastrointestinal pain—Prednisone—hematologic cancer	3.49e-05	0.000117	CcSEcCtD
Palonosetron—Nausea—Prednisolone—hematologic cancer	3.49e-05	0.000117	CcSEcCtD
Palonosetron—Myalgia—Epirubicin—hematologic cancer	3.49e-05	0.000117	CcSEcCtD
Palonosetron—Arthralgia—Epirubicin—hematologic cancer	3.49e-05	0.000117	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL6—hematologic cancer	3.48e-05	0.00135	CbGpPWpGaD
Palonosetron—Anxiety—Epirubicin—hematologic cancer	3.47e-05	0.000116	CcSEcCtD
Palonosetron—Pruritus—Betamethasone—hematologic cancer	3.47e-05	0.000116	CcSEcCtD
Palonosetron—Pruritus—Dexamethasone—hematologic cancer	3.47e-05	0.000116	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—hematologic cancer	3.47e-05	0.000116	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.46e-05	0.000116	CcSEcCtD
Palonosetron—Discomfort—Epirubicin—hematologic cancer	3.45e-05	0.000115	CcSEcCtD
Palonosetron—Vomiting—Triamcinolone—hematologic cancer	3.44e-05	0.000115	CcSEcCtD
Palonosetron—Rash—Triamcinolone—hematologic cancer	3.41e-05	0.000114	CcSEcCtD
Palonosetron—Dry mouth—Epirubicin—hematologic cancer	3.41e-05	0.000114	CcSEcCtD
Palonosetron—Dermatitis—Triamcinolone—hematologic cancer	3.41e-05	0.000114	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—hematologic cancer	3.4e-05	0.000114	CcSEcCtD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	3.39e-05	0.00132	CbGpPWpGaD
Palonosetron—Headache—Triamcinolone—hematologic cancer	3.39e-05	0.000113	CcSEcCtD
Palonosetron—CYP1A2—Phase II conjugation—GSTM1—hematologic cancer	3.38e-05	0.00131	CbGpPWpGaD
Palonosetron—Body temperature increased—Prednisone—hematologic cancer	3.38e-05	0.000113	CcSEcCtD
Palonosetron—Abdominal pain—Prednisone—hematologic cancer	3.38e-05	0.000113	CcSEcCtD
Palonosetron—Diarrhoea—Betamethasone—hematologic cancer	3.36e-05	0.000112	CcSEcCtD
Palonosetron—Diarrhoea—Dexamethasone—hematologic cancer	3.36e-05	0.000112	CcSEcCtD
Palonosetron—Anaphylactic shock—Epirubicin—hematologic cancer	3.34e-05	0.000112	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—hematologic cancer	3.34e-05	0.0013	CbGpPWpGaD
Palonosetron—Hypotension—Methotrexate—hematologic cancer	3.34e-05	0.000112	CcSEcCtD
Palonosetron—CYP1A2—Tryptophan metabolism—MDM2—hematologic cancer	3.32e-05	0.00129	CbGpPWpGaD
Palonosetron—Infection—Epirubicin—hematologic cancer	3.32e-05	0.000111	CcSEcCtD
Palonosetron—Shock—Epirubicin—hematologic cancer	3.29e-05	0.00011	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—hematologic cancer	3.28e-05	0.00011	CcSEcCtD
Palonosetron—Nervous system disorder—Epirubicin—hematologic cancer	3.28e-05	0.00011	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—hematologic cancer	3.27e-05	0.000109	CcSEcCtD
Palonosetron—CYP1A2—Biological oxidations—MTR—hematologic cancer	3.27e-05	0.00127	CbGpPWpGaD
Palonosetron—Tachycardia—Epirubicin—hematologic cancer	3.26e-05	0.000109	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.25e-05	0.000109	CcSEcCtD
Palonosetron—Skin disorder—Epirubicin—hematologic cancer	3.25e-05	0.000109	CcSEcCtD
Palonosetron—Dizziness—Dexamethasone—hematologic cancer	3.25e-05	0.000109	CcSEcCtD
Palonosetron—Dizziness—Betamethasone—hematologic cancer	3.25e-05	0.000109	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—hematologic cancer	3.23e-05	0.000108	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—hematologic cancer	3.23e-05	0.000108	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—hematologic cancer	3.23e-05	0.000108	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—hematologic cancer	3.22e-05	0.000108	CcSEcCtD
Palonosetron—Nausea—Triamcinolone—hematologic cancer	3.21e-05	0.000108	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—hematologic cancer	3.21e-05	0.000107	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.2e-05	0.000107	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—hematologic cancer	3.19e-05	0.000107	CcSEcCtD
Palonosetron—Anorexia—Epirubicin—hematologic cancer	3.19e-05	0.000107	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—hematologic cancer	3.18e-05	0.000107	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—hematologic cancer	3.18e-05	0.000106	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—hematologic cancer	3.16e-05	0.000106	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisone—hematologic cancer	3.15e-05	0.000105	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—hematologic cancer	3.14e-05	0.000105	CcSEcCtD
Palonosetron—Hypotension—Epirubicin—hematologic cancer	3.12e-05	0.000105	CcSEcCtD
Palonosetron—Vomiting—Betamethasone—hematologic cancer	3.12e-05	0.000104	CcSEcCtD
Palonosetron—Vomiting—Dexamethasone—hematologic cancer	3.12e-05	0.000104	CcSEcCtD
Palonosetron—CYP1A2—Biological oxidations—GSTT1—hematologic cancer	3.11e-05	0.00121	CbGpPWpGaD
Palonosetron—Decreased appetite—Methotrexate—hematologic cancer	3.1e-05	0.000104	CcSEcCtD
Palonosetron—Rash—Betamethasone—hematologic cancer	3.09e-05	0.000104	CcSEcCtD
Palonosetron—Rash—Dexamethasone—hematologic cancer	3.09e-05	0.000104	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—hematologic cancer	3.09e-05	0.000103	CcSEcCtD
Palonosetron—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	3.09e-05	0.0012	CbGpPWpGaD
Palonosetron—Dermatitis—Betamethasone—hematologic cancer	3.09e-05	0.000103	CcSEcCtD
Palonosetron—Dermatitis—Dexamethasone—hematologic cancer	3.09e-05	0.000103	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.08e-05	0.000103	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—hematologic cancer	3.08e-05	0.000103	CcSEcCtD
Palonosetron—Headache—Dexamethasone—hematologic cancer	3.07e-05	0.000103	CcSEcCtD
Palonosetron—Headache—Betamethasone—hematologic cancer	3.07e-05	0.000103	CcSEcCtD
Palonosetron—Infection—Doxorubicin—hematologic cancer	3.07e-05	0.000103	CcSEcCtD
Palonosetron—Asthenia—Prednisone—hematologic cancer	3.07e-05	0.000103	CcSEcCtD
Palonosetron—Pain—Methotrexate—hematologic cancer	3.05e-05	0.000102	CcSEcCtD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	3.05e-05	0.00119	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.05e-05	0.000102	CcSEcCtD
Palonosetron—Shock—Doxorubicin—hematologic cancer	3.04e-05	0.000102	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—hematologic cancer	3.03e-05	0.00118	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—hematologic cancer	3.03e-05	0.00118	CbGpPWpGaD
Palonosetron—Nervous system disorder—Doxorubicin—hematologic cancer	3.03e-05	0.000101	CcSEcCtD
Palonosetron—Pruritus—Prednisone—hematologic cancer	3.02e-05	0.000101	CcSEcCtD
Palonosetron—Insomnia—Epirubicin—hematologic cancer	3.02e-05	0.000101	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—hematologic cancer	3.02e-05	0.000101	CcSEcCtD
Palonosetron—Skin disorder—Doxorubicin—hematologic cancer	3e-05	0.000101	CcSEcCtD
Palonosetron—Paraesthesia—Epirubicin—hematologic cancer	3e-05	0.0001	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—hematologic cancer	2.98e-05	0.00116	CbGpPWpGaD
Palonosetron—Dyspnoea—Epirubicin—hematologic cancer	2.98e-05	9.97e-05	CcSEcCtD
Palonosetron—Somnolence—Epirubicin—hematologic cancer	2.97e-05	9.94e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—hematologic cancer	2.97e-05	0.00115	CbGpPWpGaD
Palonosetron—Anorexia—Doxorubicin—hematologic cancer	2.95e-05	9.87e-05	CcSEcCtD
Palonosetron—Dyspepsia—Epirubicin—hematologic cancer	2.94e-05	9.85e-05	CcSEcCtD
Palonosetron—Diarrhoea—Prednisone—hematologic cancer	2.92e-05	9.79e-05	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—hematologic cancer	2.92e-05	9.77e-05	CcSEcCtD
Palonosetron—Nausea—Dexamethasone—hematologic cancer	2.92e-05	9.75e-05	CcSEcCtD
Palonosetron—Nausea—Betamethasone—hematologic cancer	2.92e-05	9.75e-05	CcSEcCtD
Palonosetron—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	2.91e-05	0.00113	CbGpPWpGaD
Palonosetron—Decreased appetite—Epirubicin—hematologic cancer	2.91e-05	9.72e-05	CcSEcCtD
Palonosetron—Hypotension—Doxorubicin—hematologic cancer	2.89e-05	9.67e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—hematologic cancer	2.89e-05	0.00112	CbGpPWpGaD
Palonosetron—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.89e-05	9.66e-05	CcSEcCtD
Palonosetron—Fatigue—Epirubicin—hematologic cancer	2.88e-05	9.64e-05	CcSEcCtD
Palonosetron—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	2.87e-05	0.00111	CbGpPWpGaD
Palonosetron—Pain—Epirubicin—hematologic cancer	2.86e-05	9.56e-05	CcSEcCtD
Palonosetron—Constipation—Epirubicin—hematologic cancer	2.86e-05	9.56e-05	CcSEcCtD
Palonosetron—Dizziness—Prednisone—hematologic cancer	2.83e-05	9.46e-05	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—hematologic cancer	2.82e-05	9.45e-05	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—hematologic cancer	2.82e-05	9.45e-05	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.82e-05	9.43e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—hematologic cancer	2.8e-05	0.00109	CbGpPWpGaD
Palonosetron—Insomnia—Doxorubicin—hematologic cancer	2.8e-05	9.36e-05	CcSEcCtD
Palonosetron—Paraesthesia—Doxorubicin—hematologic cancer	2.78e-05	9.29e-05	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—hematologic cancer	2.76e-05	9.23e-05	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—hematologic cancer	2.75e-05	9.2e-05	CcSEcCtD
Palonosetron—Gastrointestinal pain—Epirubicin—hematologic cancer	2.73e-05	9.15e-05	CcSEcCtD
Palonosetron—Dyspepsia—Doxorubicin—hematologic cancer	2.72e-05	9.11e-05	CcSEcCtD
Palonosetron—Vomiting—Prednisone—hematologic cancer	2.72e-05	9.09e-05	CcSEcCtD
Palonosetron—Rash—Prednisone—hematologic cancer	2.69e-05	9.02e-05	CcSEcCtD
Palonosetron—Dermatitis—Prednisone—hematologic cancer	2.69e-05	9.01e-05	CcSEcCtD
Palonosetron—Decreased appetite—Doxorubicin—hematologic cancer	2.69e-05	9e-05	CcSEcCtD
Palonosetron—Headache—Prednisone—hematologic cancer	2.68e-05	8.96e-05	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.67e-05	8.93e-05	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—hematologic cancer	2.67e-05	8.92e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—hematologic cancer	2.67e-05	0.00104	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—EP300—hematologic cancer	2.67e-05	0.00104	CbGpPWpGaD
Palonosetron—Constipation—Doxorubicin—hematologic cancer	2.64e-05	8.85e-05	CcSEcCtD
Palonosetron—Pain—Doxorubicin—hematologic cancer	2.64e-05	8.85e-05	CcSEcCtD
Palonosetron—Body temperature increased—Epirubicin—hematologic cancer	2.64e-05	8.84e-05	CcSEcCtD
Palonosetron—Abdominal pain—Epirubicin—hematologic cancer	2.64e-05	8.84e-05	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.64e-05	0.00102	CbGpPWpGaD
Palonosetron—Hypersensitivity—Methotrexate—hematologic cancer	2.63e-05	8.81e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—hematologic cancer	2.59e-05	0.00101	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—SRC—hematologic cancer	2.59e-05	0.00101	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	2.57e-05	0.000997	CbGpPWpGaD
Palonosetron—Asthenia—Methotrexate—hematologic cancer	2.56e-05	8.58e-05	CcSEcCtD
Palonosetron—CYP2D6—Biological oxidations—GSTP1—hematologic cancer	2.54e-05	0.000988	CbGpPWpGaD
Palonosetron—Nausea—Prednisone—hematologic cancer	2.54e-05	8.49e-05	CcSEcCtD
Palonosetron—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.53e-05	8.46e-05	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—hematologic cancer	2.53e-05	8.46e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—hematologic cancer	2.52e-05	0.000981	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—MTR—hematologic cancer	2.52e-05	0.00098	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTP1—hematologic cancer	2.51e-05	0.000974	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—hematologic cancer	2.49e-05	0.000969	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ALB—hematologic cancer	2.47e-05	0.000959	CbGpPWpGaD
Palonosetron—Hypersensitivity—Epirubicin—hematologic cancer	2.46e-05	8.24e-05	CcSEcCtD
Palonosetron—Body temperature increased—Doxorubicin—hematologic cancer	2.44e-05	8.18e-05	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—hematologic cancer	2.44e-05	8.18e-05	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—hematologic cancer	2.44e-05	8.18e-05	CcSEcCtD
Palonosetron—Asthenia—Epirubicin—hematologic cancer	2.4e-05	8.03e-05	CcSEcCtD
Palonosetron—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	2.4e-05	0.000932	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	2.39e-05	0.000928	CbGpPWpGaD
Palonosetron—Pruritus—Epirubicin—hematologic cancer	2.36e-05	7.91e-05	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—hematologic cancer	2.36e-05	7.9e-05	CcSEcCtD
Palonosetron—CYP2D6—Biological oxidations—GSTM1—hematologic cancer	2.34e-05	0.000908	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—hematologic cancer	2.32e-05	0.000903	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hematologic cancer	2.32e-05	0.0009	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTM1—hematologic cancer	2.3e-05	0.000895	CbGpPWpGaD
Palonosetron—Diarrhoea—Epirubicin—hematologic cancer	2.29e-05	7.65e-05	CcSEcCtD
Palonosetron—Hypersensitivity—Doxorubicin—hematologic cancer	2.28e-05	7.62e-05	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—hematologic cancer	2.27e-05	7.6e-05	CcSEcCtD
Palonosetron—Rash—Methotrexate—hematologic cancer	2.25e-05	7.54e-05	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—hematologic cancer	2.25e-05	7.53e-05	CcSEcCtD
Palonosetron—Headache—Methotrexate—hematologic cancer	2.24e-05	7.49e-05	CcSEcCtD
Palonosetron—Asthenia—Doxorubicin—hematologic cancer	2.22e-05	7.43e-05	CcSEcCtD
Palonosetron—Dizziness—Epirubicin—hematologic cancer	2.21e-05	7.4e-05	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—hematologic cancer	2.19e-05	7.32e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hematologic cancer	2.16e-05	0.000841	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hematologic cancer	2.16e-05	0.000841	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTP1—hematologic cancer	2.15e-05	0.000837	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—hematologic cancer	2.15e-05	0.000834	CbGpPWpGaD
Palonosetron—Vomiting—Epirubicin—hematologic cancer	2.13e-05	7.11e-05	CcSEcCtD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTP1—hematologic cancer	2.12e-05	0.000826	CbGpPWpGaD
Palonosetron—Nausea—Methotrexate—hematologic cancer	2.12e-05	7.1e-05	CcSEcCtD
Palonosetron—Diarrhoea—Doxorubicin—hematologic cancer	2.12e-05	7.08e-05	CcSEcCtD
Palonosetron—Rash—Epirubicin—hematologic cancer	2.11e-05	7.05e-05	CcSEcCtD
Palonosetron—Dermatitis—Epirubicin—hematologic cancer	2.11e-05	7.05e-05	CcSEcCtD
Palonosetron—Headache—Epirubicin—hematologic cancer	2.09e-05	7.01e-05	CcSEcCtD
Palonosetron—Dizziness—Doxorubicin—hematologic cancer	2.05e-05	6.84e-05	CcSEcCtD
Palonosetron—Nausea—Epirubicin—hematologic cancer	1.99e-05	6.64e-05	CcSEcCtD
Palonosetron—CYP1A2—Biological oxidations—GSTM1—hematologic cancer	1.98e-05	0.000769	CbGpPWpGaD
Palonosetron—Vomiting—Doxorubicin—hematologic cancer	1.97e-05	6.58e-05	CcSEcCtD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTM1—hematologic cancer	1.95e-05	0.000759	CbGpPWpGaD
Palonosetron—Rash—Doxorubicin—hematologic cancer	1.95e-05	6.53e-05	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—hematologic cancer	1.95e-05	6.52e-05	CcSEcCtD
Palonosetron—CYP2D6—Metabolism—PHYH—hematologic cancer	1.95e-05	0.000757	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—FTCD—hematologic cancer	1.95e-05	0.000757	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GMPS—hematologic cancer	1.95e-05	0.000757	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	1.95e-05	0.000757	CbGpPWpGaD
Palonosetron—Headache—Doxorubicin—hematologic cancer	1.94e-05	6.48e-05	CcSEcCtD
Palonosetron—Nausea—Doxorubicin—hematologic cancer	1.84e-05	6.15e-05	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—hematologic cancer	1.82e-05	0.000709	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SMPD3—hematologic cancer	1.78e-05	0.000692	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	1.7e-05	0.000661	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	1.66e-05	0.000646	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PHYH—hematologic cancer	1.65e-05	0.000641	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—FTCD—hematologic cancer	1.65e-05	0.000641	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GMPS—hematologic cancer	1.65e-05	0.000641	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	1.64e-05	0.000637	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	1.63e-05	0.000635	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ASNS—hematologic cancer	1.56e-05	0.000605	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—B3GAT1—hematologic cancer	1.56e-05	0.000605	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—DCK—hematologic cancer	1.56e-05	0.000605	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	1.56e-05	0.000605	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	1.54e-05	0.000598	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	1.53e-05	0.000594	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SMPD3—hematologic cancer	1.51e-05	0.000587	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	1.51e-05	0.000585	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	1.51e-05	0.000585	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HDC—hematologic cancer	1.48e-05	0.000574	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	1.41e-05	0.000547	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	1.37e-05	0.000533	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CDA—hematologic cancer	1.35e-05	0.000525	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—B3GAT1—hematologic cancer	1.32e-05	0.000513	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ASNS—hematologic cancer	1.32e-05	0.000513	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—DCK—hematologic cancer	1.32e-05	0.000513	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PC—hematologic cancer	1.3e-05	0.000505	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	1.29e-05	0.000501	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GMPS—hematologic cancer	1.27e-05	0.000495	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—FTCD—hematologic cancer	1.27e-05	0.000495	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PHYH—hematologic cancer	1.27e-05	0.000495	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GBA—hematologic cancer	1.26e-05	0.000488	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC35B2—hematologic cancer	1.26e-05	0.000488	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HDC—hematologic cancer	1.25e-05	0.000486	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	1.17e-05	0.000453	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.16e-05	0.000453	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—MTAP—hematologic cancer	1.15e-05	0.000446	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CDA—hematologic cancer	1.14e-05	0.000445	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PC—hematologic cancer	1.1e-05	0.000428	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GBA—hematologic cancer	1.06e-05	0.000413	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC35B2—hematologic cancer	1.06e-05	0.000413	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—FHL2—hematologic cancer	1.02e-05	0.000398	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—DCK—hematologic cancer	1.02e-05	0.000396	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ASNS—hematologic cancer	1.02e-05	0.000396	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.02e-05	0.000396	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—AGRN—hematologic cancer	1e-05	0.00039	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MTAP—hematologic cancer	9.73e-06	0.000378	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HDC—hematologic cancer	9.65e-06	0.000375	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—IDH2—hematologic cancer	9.51e-06	0.00037	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HMMR—hematologic cancer	9.51e-06	0.00037	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ARNTL—hematologic cancer	8.94e-06	0.000348	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CDA—hematologic cancer	8.83e-06	0.000343	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CA9—hematologic cancer	8.7e-06	0.000338	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ACP5—hematologic cancer	8.7e-06	0.000338	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—FHL2—hematologic cancer	8.67e-06	0.000337	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NCOR2—hematologic cancer	8.59e-06	0.000334	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—AGRN—hematologic cancer	8.5e-06	0.00033	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PC—hematologic cancer	8.5e-06	0.00033	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GBA—hematologic cancer	8.21e-06	0.000319	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC35B2—hematologic cancer	8.21e-06	0.000319	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—IDH1—hematologic cancer	8.18e-06	0.000318	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ABCC3—hematologic cancer	8.09e-06	0.000314	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTO1—hematologic cancer	8.09e-06	0.000314	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TXN—hematologic cancer	8.09e-06	0.000314	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—IDH2—hematologic cancer	8.06e-06	0.000313	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HMMR—hematologic cancer	8.06e-06	0.000313	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SPHK1—hematologic cancer	7.92e-06	0.000308	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—UGT1A1—hematologic cancer	7.6e-06	0.000296	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	7.6e-06	0.000295	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ARNTL—hematologic cancer	7.58e-06	0.000295	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MTAP—hematologic cancer	7.51e-06	0.000292	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC22A1—hematologic cancer	7.4e-06	0.000288	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CRABP1—hematologic cancer	7.4e-06	0.000288	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CA9—hematologic cancer	7.37e-06	0.000286	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ACP5—hematologic cancer	7.37e-06	0.000286	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NCOR2—hematologic cancer	7.27e-06	0.000283	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALOX5—hematologic cancer	7.21e-06	0.00028	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NUP98—hematologic cancer	6.98e-06	0.000271	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—IDH1—hematologic cancer	6.93e-06	0.000269	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TXN—hematologic cancer	6.85e-06	0.000266	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ABCC3—hematologic cancer	6.85e-06	0.000266	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTO1—hematologic cancer	6.85e-06	0.000266	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NCOA3—hematologic cancer	6.78e-06	0.000263	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ADCY7—hematologic cancer	6.78e-06	0.000263	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NUP214—hematologic cancer	6.73e-06	0.000262	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SPHK1—hematologic cancer	6.71e-06	0.000261	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—FHL2—hematologic cancer	6.69e-06	0.00026	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—MTR—hematologic cancer	6.59e-06	0.000256	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ABCG2—hematologic cancer	6.59e-06	0.000256	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AGRN—hematologic cancer	6.56e-06	0.000255	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ENO2—hematologic cancer	6.47e-06	0.000251	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—UGT1A1—hematologic cancer	6.44e-06	0.00025	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTT1—hematologic cancer	6.27e-06	0.000244	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CRABP1—hematologic cancer	6.27e-06	0.000244	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC22A1—hematologic cancer	6.27e-06	0.000244	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HMMR—hematologic cancer	6.22e-06	0.000242	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—IDH2—hematologic cancer	6.22e-06	0.000242	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SDC1—hematologic cancer	6.13e-06	0.000238	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALOX5—hematologic cancer	6.11e-06	0.000237	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NUP98—hematologic cancer	5.91e-06	0.00023	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ARNTL—hematologic cancer	5.85e-06	0.000227	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ADCY7—hematologic cancer	5.74e-06	0.000223	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NCOA3—hematologic cancer	5.74e-06	0.000223	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NUP214—hematologic cancer	5.7e-06	0.000222	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CA9—hematologic cancer	5.69e-06	0.000221	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ACP5—hematologic cancer	5.69e-06	0.000221	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	5.64e-06	0.000219	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NCOR2—hematologic cancer	5.61e-06	0.000218	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ABCG2—hematologic cancer	5.59e-06	0.000217	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MTR—hematologic cancer	5.59e-06	0.000217	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ENO2—hematologic cancer	5.48e-06	0.000213	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—IDH1—hematologic cancer	5.35e-06	0.000208	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTT1—hematologic cancer	5.31e-06	0.000207	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TXN—hematologic cancer	5.29e-06	0.000206	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTO1—hematologic cancer	5.29e-06	0.000206	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ABCC3—hematologic cancer	5.29e-06	0.000206	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	5.23e-06	0.000203	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NQO1—hematologic cancer	5.21e-06	0.000203	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CD44—hematologic cancer	5.21e-06	0.000203	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SDC1—hematologic cancer	5.19e-06	0.000202	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SPHK1—hematologic cancer	5.18e-06	0.000201	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.97e-06	0.000193	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.96e-06	0.000193	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYCS—hematologic cancer	4.93e-06	0.000192	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	4.9e-06	0.00019	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.9e-06	0.00019	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC22A1—hematologic cancer	4.84e-06	0.000188	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CRABP1—hematologic cancer	4.84e-06	0.000188	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.71e-06	0.000183	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.68e-06	0.000182	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NUP98—hematologic cancer	4.56e-06	0.000177	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.43e-06	0.000172	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.43e-06	0.000172	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NQO1—hematologic cancer	4.42e-06	0.000172	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CD44—hematologic cancer	4.42e-06	0.000172	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NUP214—hematologic cancer	4.4e-06	0.000171	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.35e-06	0.000169	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.32e-06	0.000168	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MTR—hematologic cancer	4.31e-06	0.000168	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.31e-06	0.000168	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ENO2—hematologic cancer	4.23e-06	0.000164	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYCS—hematologic cancer	4.18e-06	0.000162	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	4.15e-06	0.000161	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.12e-06	0.00016	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.1e-06	0.000159	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SDC1—hematologic cancer	4.01e-06	0.000156	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTM1—hematologic cancer	3.99e-06	0.000155	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NCOR1—hematologic cancer	3.99e-06	0.000155	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.74e-06	0.000145	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTP1—hematologic cancer	3.68e-06	0.000143	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.56e-06	0.000138	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—MTHFR—hematologic cancer	3.53e-06	0.000137	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ABCB1—hematologic cancer	3.49e-06	0.000135	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CD44—hematologic cancer	3.41e-06	0.000132	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NQO1—hematologic cancer	3.41e-06	0.000132	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTM1—hematologic cancer	3.38e-06	0.000132	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NCOR1—hematologic cancer	3.38e-06	0.000132	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYCS—hematologic cancer	3.22e-06	0.000125	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.2e-06	0.000125	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.99e-06	0.000116	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.97e-06	0.000115	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.84e-06	0.00011	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.75e-06	0.000107	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.69e-06	0.000105	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.64e-06	0.000102	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.61e-06	0.000102	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.61e-06	0.000102	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.61e-06	0.000101	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALB—hematologic cancer	2.57e-06	0.0001	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.51e-06	9.77e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.46e-06	9.57e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CREBBP—hematologic cancer	2.33e-06	9.06e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.31e-06	8.97e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.27e-06	8.83e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.21e-06	8.59e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALB—hematologic cancer	2.18e-06	8.48e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3R1—hematologic cancer	2.09e-06	8.11e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTEN—hematologic cancer	1.96e-06	7.63e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.94e-06	7.54e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.93e-06	7.48e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—EP300—hematologic cancer	1.87e-06	7.28e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.8e-06	6.99e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.7e-06	6.63e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALB—hematologic cancer	1.68e-06	6.54e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTEN—hematologic cancer	1.66e-06	6.47e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.61e-06	6.26e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—EP300—hematologic cancer	1.59e-06	6.17e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.49e-06	5.78e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.39e-06	5.39e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTEN—hematologic cancer	1.28e-06	4.99e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—EP300—hematologic cancer	1.22e-06	4.76e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.17e-06	4.56e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—AKT1—hematologic cancer	1.13e-06	4.4e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—AKT1—hematologic cancer	9.59e-07	3.73e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CA—hematologic cancer	9.06e-07	3.52e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AKT1—hematologic cancer	7.4e-07	2.88e-05	CbGpPWpGaD
